menu
    • menu

    Company profile for AvenCell Therapeutics

    NEW Drugs in Dev: 5
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AvenCell Therapeutics, Inc. was recently launched by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics and incorporated the clinical-stage biopharmaceutical company GEMoaB GmbH, now named AvenCell Europe GmbH. With $250 million in committed capital from Blackstone as its sole founding investor, AvenCell brings together switchable universal T cell technology developed by the former Cellex subsi...
    AvenCell Therapeutics, Inc. was recently launched by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics and incorporated the clinical-stage biopharmaceutical company GEMoaB GmbH, now named AvenCell Europe GmbH. With $250 million in committed capital from Blackstone as its sole founding investor, AvenCell brings together switchable universal T cell technology developed by the former Cellex subsidiary GEMoaB GmbH.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AvenCell TherapeuticsGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Tatzberg 47 01307 Dresden
    Telephone
    Telephone
    +49 351 4466 4500
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://avencell.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AvenCell Doses First Patient in Phase I QUADvance AVC-203 Study
    AvenCell Doses First Patient in Phase I QUADvance AVC-203 Study

    02 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/avencell-therapeutics-announces-first-patient-dosed-in-phase-i-quadvance-study-with-avc-203-a-novel-allogeneic-cd19cd20-dual-targeting-car-t-investigational-therapy-for-the-treatment-of-relapsedrefractory-b-cell-malignancies-302732100.html

    PR NEWSWIRE
    02 Apr 2026
    Share Share
    ViroCell & AvenCell Collaborate on CAR-T for Blood Cancers
    ViroCell & AvenCell Collaborate on CAR-T for Blood Cancers

    29 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250728879540/en/ViroCell-Biologics-and-AvenCell-Therapeutics-Announce-Retroviral-Vector-Manufacturing-Collaboration-to-Accelerate-Development-of-Novel-Allogeneic-CAR-T-Therapies-for-Blood-Cancers

    BUSINESSWIRE
    29 Jul 2025
    Share Share
    AvenCell bags $112M to flick 'switchable' CAR-Ts in the clinic
    AvenCell bags $112M to flick 'switchable' CAR-Ts in the clinic

    22 Oct 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/avencell-secures-112m-series-b-flick-switchable-car-ts-clinic

    FIERCE BIOTECH
    22 Oct 2024
    Share Share
    AvenCell Presents Data from CD123-Directed Universal CAR T Cell Therapy Program
    AvenCell Presents Data from CD123-Directed Universal CAR T Cell Therapy Program

    12 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221212005828/en

    BUSINESSWIRE
    12 Dec 2022
    Share Share
    AvenCell to Present New Data from Lead Universal CAR T Therapy
    AvenCell to Present New Data from Lead Universal CAR T Therapy

    03 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221103006127/en/AvenCell-to-Present-New-Data-from-Lead-Universal-CAR-T-Cell-Therapy-Program-at-64th-American-Society-of-Hematology-Annual-Meeting-and-Exposition

    BUSINESSWIRE
    03 Nov 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search